Novartis reveals results from pivotal CML survey
International data questions the assumption that chronic myeloid leukaemia is now a ‘solved’ disease
Read More
Tag: CML
Novartis’ Scemblix approved by the EC for adults with chronic myeloid leukaemia
It is estimated that every year more than 6,300 people will be diagnosed with CML in Europe
Read More
First-line use of Pfizer’s Bosulif cleared in the US
Pfizer’s Bosulif has been approved in the US to treat patients with newly-diagnosed Ph+ chronic myelogenous leukemia.
Read More
BMS, Novartis to test Mekinist/Opdivo combo
Novartis and Bristol-Myers Squibb have signed a clinical research pact to investigate the safety, tolerability, and efficacy of combining their respective drugs Mekinist and Opdivo.
Read More
CML patients in England win access to Incyte’s Iclusig
Chronic Myeloid Leukaemia (CML) patients in England who are resistant or intolerant to second generation tyrosine kinase inhibitor (TKI) therapies are on the brink of getting full-access to Incyte’s Iclusig on the NHS following a nod from NICE.
Read More
NICE backs routine use of Incyte’s leukaemia drug
Draft guidelines published by the National Institute for Health and Care Excellence back the routine use of Incyte’s Iclusig on the NHS to treat some patients with chronic myeloid leukaemia and acute lymphoblastic leukaemia.
Read More
Pfizer, Avillion’s Bosulif comes out on top in first-line CML trial
Pfizer and partner Avillion have presented data from a late-stage study showing that Bosulif was better than Novartis’ Gleevec as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.
Read More
SMC clears three new drugs for NHS Scotland use
Three new medicines have been endorsed for routine use on the NHS giving patients new options for skin cancer, chronic myeloid leukaemia, and anticoagulant reversal.
Read More
NICE backs Pfizer’s Bosulif for CML
NHS use of Pfizer’s Bosulif is being endorsed by the National Institute for Health and Care Excellence to treat some patients with chronic myeloid leukaemia, in a move which, if confirmed in final guidelines, could significantly widen access to the drug.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
